Polymeric prodrugs of 5-fluorouracil

Journal of Controlled Release

Volumn 48, Issue 2-3, 1997, Pages 165-178

  Nichifor, Marieta ^a,c   Schacht, Etienne H ^a   Seymour, Leonard W ^b  

^a GHENT UNIVERSITY   (Belgium)

^b UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

^c PETRU PONI INSTITUTE OF MACROMOLECULAR CHEMISTRY   (Romania)

Author keywords

5 Fluorouracil; Collagenase; Lysosomal enzymes; Prodrugs

Indexed keywords

CATHEPSIN B; FLUOROURACIL; FLUOROURACIL DERIVATIVE; GELATINASE A; LYSOSOME ENZYME; PRODRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; COLORECTAL CARCINOMA; CYTOTOXICITY; DRUG CONJUGATION; DRUG RELEASE; DRUG STABILITY; DRUG SYNTHESIS; NONHUMAN; PRIORITY JOURNAL; RAT; REVIEW;

EID: 0030769244     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(97)00048-5     Document Type: Article

References (48)

1. H. Sezaki, Y. Takakura and M. Hashida, Soluble macromolecular carriers for the delivery of antitumor drugs, Adv. Drug Del. Rev. 3 (1989) 247-266.
2. P. Sinko and J. Kohn, Polymeric drug delivery systems, in: M. El Nokali, D.M. Piatt and B.A. Charpantier (Eds.) Polymeric Delivery Systems. Properties and Applications, ACS Symposium Series 520, Washington DC, 1993, pp. 18-36.
3. H. Maeda and T. Matsumura, Tumoritropic and lymphotropic principles of macromolecular drugs, CRC Crit. Rev. Ther. Drug Carrier Syst. 6 (1989) 193-201.
4. L.W. Seymour, Passive tumor targeting of soluble macromolecules and drug conjugates, CRC Crit. Rev. Ther. Drug Carrier Syst. 9 (1992) 135-187.
5. M.M. Ponpipom, R.L. Bugiaresi, J.C. Robbins, T.W Duebber and T.Y. Shen, Cell-specific ligands for selective drug delivery to tissues and organs, J. Med. Chem. 24 (1981) 1388-1395.
6. B. Rihova, N.L. Krinik and J. Kopecek, Targetable photoactivable drugs. 3. In vitro efficacy of polymer bound chlorin e6 toward human hepatocarcinoma cell line (PLC/PRF/5) targeted with galactosamine and to mouse splenocytes targeted with anti-Thy 1.2 antibodies. J. Control. Release 25 (1993) 71-87.
7. S. Vansteenkiste, E. Schacht, R. Duncan, L. Seymour, I. Pawluczyk and R. Baldwin, Fate of glycosylated dextrans after in vivo administration. J. Control. Release 16 (1991) 91-100.
8. A.K. Gonsho, K. Irie, H. Susaki, H. Iwasawa, S. Okuno and T. Sugawara, Tissue-targeting ability of saccharide-poly(L-lysine) conjugates, Biol. Pharm. Bull. 17 (1994) 275-282.
9. C.R. Gardner, Potential limitations of drug targeting: an overview, Biomaterials 6 (1985) 153-160.
10. A. Trouet, M. Masquelier, R. Baurain and D. Deprez-De Campeneere, A covalent linkage between daunomycin and proteins that is stable in serum and reversible by lysosomal hydrolyses, as required for a lysosomotropic drug-carrier conjugate: in vitro and in vivo studies. Proc. Natl. Acad. Sci. USA 79 (1982) 626-629.
11. R. Duncan, H. Cable, J. Lloyd, P. Rejmanova and J. Kopecek, Polymers containing enzymatically degradable bonds. 7. Design of oligopeptide side-chain in poly[N-(2-hydroxypropyl)methacrylamide] copolymers to promote efficient degradation by lysosomal enzymes. Makromol. Chem. 184 (1983) 1997-2008.
12. R. Duncan, L.W. Seymour, K. Ulbrich and J. Kopecek, Soluble synthetic polymers for targeting and controlled release of anticancer agents, particularly anthracycline antibiotics, J. Bioact. Comp. Polymers 3 (1988) 4-15.
13. C.J.T. Hoes, J. Grootoonk, R. Duncan, I.C. Hume, M. Bhakoo, J.M.W. Bouma and J. Feijen, Biological properties of adriamycin bound to biodegradable polymeric carriers, J. Control. Release 23 (1993) 37-54.
14. A. De Marre, L.W. Seymour and E. Schacht, Evaluation of the hydrolytic and enzymatic stability of macromolecular mitomycin C derivatives, J. Control. Release 31 (1994) 89-97.
15. C. De Duve, Lysosomes, a new group of cytoplasmic particles, in: T. Hayashi (Ed.) Subcellular particles, Ronald Press, New York, 1959, pp. 128-159.
16. L.A. Liotta, N.C. Rao and U.M. Wewer, Biochemical interactions of the tumor cells with basement membrane, Annu. Rev. Biochem. 55 (1986) 1037-1057.
17. K. Tryggvason, M. Hoyhtya and M. Saho, Proteolytic degradation of extracellular matrix in tumor invasion, Biochim. Biophys. Acta 907 (1987) 191-217.
18. M.S. Naylor, G.W Stamp, B.D. Davies and F.R. Balkwill, Expression and activity of MMPs and their regulators in ovarian cancer, Int. J. Cancer 58 (1994) 50-56.
19. L. David, J.M. Nesland, R. Holm and M. Sobrinho-Simoes, Expression of laminin, collagen IV, fibronectin and type IV collagenase in gastric carcinoma, Cancer 73 (1994) 518-527.
20. E. Campo, J. Munoz, R. Miquel, A. Palacin, A. Cardesa, B.F. Sloane and M.R. Emmert-Buck, Cathepsin B expression in colorectal carcinomas correlates with tumor progression and shortened patient survival, Am. J. Pathol. 145 (1994) 301-309.
21. E. Weber, D. Günther, F. Laube, B. Wiederanders and H. Kirschke, Hybridoma cells producing antibodies to cathepsin L have greatly reduced potential for tumor growth, J. Cancer Res. Clin. Oncol. 120 (1994) 564-567.
22. E. Liaudet, M. Garcia and H. Rochefort, Cathepsin D maturation and its stimulatory effect on metastasis are prevented by addition of KDEL retention signal, Oncogene 9 (1994) 1145-1154.
23. T.L. Moser, T.N. Young, G.C. Rodriguez, S.V. Pizzo, R.C. Bast and M. Sharon Stack, Secretion of extracellular matrix-degrading proteinases is increased in epithelial ovarian carcinoma, Int. J. Cancer 56 (1994) 552-559.
24. J.-D. Vassalli and M.S. Pepper, Membrane proteases in focus, Nature 370 (1994) 14-16.
25. J.A. Uría, A.A. Ferrando, G. Velasco, J.M.P. Freije and C. López-Otín, Structure and expression in breast tumors of human TIMP-3, a new member of the metallopronase inhibitor family, Cancer Res. 54 (1994) 2091-2094.
26. P. Calabresi and R.E. Parks, Jr., Antimetabolites, in: L.S. Goodman, T.W. Raal and F. Murad (Eds.) Pharmacological Basis of Therapeutics, McMillan, New York, 1985, pp. 1268-1276.
27. M. Akashi and K. Takemoto, New aspects of polymer drugs, Adv. Polymer Sci. 97 (1990) 108-146.
28. T. Ouchi, A. Fujino, K. Tanaka and Y. Banba, Synthesis and antitumor activity of conjugates of poly(α-malic acid) and 5-fluorouracil bound via ester, amide or carbamoyl bonds, J. Control. Release 12 (1990) 143-153.
29. T. Ouchi, Y Hagihara, K. Takahashi, Y. Takano and I. Igarashi, Synthesis and anti-tumor activity of poly(ethylene glycol)s linked to 5-fluorouracil via urethane or urea bonds, Drug Design Disc. 9 (1992) 93-105.
30. T. Ouchi, T. Banba, T. Matsumoto, S. Suzuki and M. Suzuki, Synthesis and anti-tumor activity of conjugates of 5-fluoro-uracil and chito-oligosaccharides involving a hexamethylene spacer group and carbamoyl bonds, Drug Design Del. 6 (1990) 281-287.
31. H. Bundgaard, The double prodrug concept and its application, Adv. Drug Del. Rev. 3 (1989) 39-65.
32. K.L. Amsberry and R.T. Borchardt, Amine prodrugs which utilise hydroxy amide lactonization. I. A potential redox-sensitive amide prodrug, Pharm. Res. 8 (1991) 323-330.
33. T. Nishitani, T. Iwasaki, Y Mushika and M. Miyoshi, Synthesis of 2-(pyrimidine-1-yl) and 2-(purine-9-yl)-2-amino acids, J. Org. Chem. 44 (1979) 2019-2023.
34. W.D. Kingsburry, J.C. Boehm, R.J. Mehta, S.F. Grapel and Ch. Gilvarg, A novel peptide delivery system involving peptidase activated prodrugs as antimicrobial agents. Synthesis and biological activity of peptidyl derivatives of 5-fluorouracil, J. Med. Chem. 27 (1984) 1447-1451.
35. M. Nichifor, V. Coessens and H. Schacht, Macromolecular prodrugs of 5-fluorouracil. 1. Synthesis and hydrolytic stability, J. Bioact. Comp. Polymers 10 (1995) 199-222.
36. M. Nichifor and E. Schacht, Synthesis of peptide derivatives of 5-fluorouracil, Tetrahedron 50 (1994) 3747-3760.
37. M. Nichifor and E. Schacht, Synthesis of diastereomerically pure oligopeptide derivatives of 5-fluorouracil, Tetrahedron Lett, (in press).
38. P. Caliceti, C. Monfardini, L. Sartore, O. Schiavon, F. Baccichetti, F. Carlassare and F.M. Veronese, Preparation and properties of monoethoxy poly(ethylene glycol) doxorubicin conjugates linked by an amino acid or a peptide as spacer, Il Farmaco 48 (1993) 919-932.
39. T. Ouchi, H. Kuroda, K. Hirai and Y. Ohya, Design of drug-terminated poly(ethylene glycol) conjugate exhibiting antitumor activity, Macromol. Rep. A31 (1994) 1091-1099.
40. A.S. Williams and G. Taylor, Synthesis, characterization and release of cromoglycate from dextran conjugates, Int. J. Pharm. 83 (1992) 233-239.
41. W. Dang, O.M. Colvin, H. Brem and W.M. Saltzman, Covalent coupling of methotrexate to dextran enhances the penetration of cytotoxicity into a tissue-like matrix, Cancer Res. 54 (1994) 1729-1735.
42. S. Danhause-Riedl, E. Hausmann, H.-D. Schick, R. Bender, H. Dietzfelbinger, J. Rastetter and A.-R. Hanauske, Phase I clinical trial of dextran conjugated doxorubicin (AD-70, DOX-OXD), Invest. New Drugs 11 (1993) 187-195.
43. A. De Marre, H. Soyez and E. Schacht, Synthesis of macromolecular mitomycin C derivatives, J. Control. Release 32 (1994) 129-137.
44. J.C. Ramirez, M. Sanchez-Chaves and F. Arranz, Dextran functionalized by cyclic carbonate groups as support of bioactive compounds, Angew. Makromol. Chem. 206 (1993) 77-85.
45. F. Vandoorne, D. Vercauteren, D. Permentier and E.H. Schacht, Reinvestigation of 4-nitrophenyl chloroformate activation of dextran. Evidence of formation of different types of carbonate moieties, Makromol. Chem. 186 (1985) 2455-2460.
46. 5-(2-hydroxyethyl)-L-glutamine], Makromol. Chem. 193 (1992) 3023-3030.
47. 5-(2-hydroxyethyl)-L-glutamine] by aminolysis of poly(γ-benzyl glutamate), Polymer 11 (1993) 2443-2446.
48. M. Nichifor, E.H. Schacht and L.W. Seymour, Macromolecular prodrugs of 5-fluorouracil. 2. Enzymatic degradation, J. Control. Release 39 (1996) 79-92.